Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy : Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group
Spanjaart, Anne Mea (Cancer Center Amsterdam and LYMMCARE (Països Baixos))
Ljungman, Per (Karolinska University Hospital)
Tridello, Gloria (European Society for Blood and Marrow Transplantation (EBMT) Data Office (Països Baixos))
Schwartz, Juana (European Society for Blood and Marrow Transplantation (EBMT) Leiden Study Unit (Països Baixos))
Martínez Cibrián, Núria (Hospital Clínic i Provincial de Barcelona)
Barba, Pere (Hospital Universitari Vall d'Hebron)
Kwon, Mi (Hospital G. Universitario Gregorio Marañon (Madrid))
López Corral, Lucia (Hospital Universitario de Salamanca and IBSAL)
Martínez-López, Joaquín (Hospital Univ. 12 de Octubre (Madrid))
Ferrá, Christelle (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Di Blasi, Roberta (Assistance Publique Hôpitaux de Paris-Hopital Saint-Louis (França))
Ghesquieres, Herve (Hospices Civils de Lyon (França))
Mutsaers, Pim (Erasmus MC Cancer Center (rotterdam, Països Baixos))
Calkoen, Friso (Princess Máxima Center for Pediatric Oncology (Utrecht, Països Baixos))
Jak, Margot (University Medical Center Utrecht (Utrecht, Països Baixos))
van Doesum, Jaap A. (University Medical Center Groningen (Països Baixos))
Vermaat, Joost S. P. (Leiden University Medical Center (Leider, Països Baixos))
van der Poel, Marjolein (Maastricht University Medical Center (Leider, Països Baixos))
Maertens, Johan (University Hospitals Gasthuisberg (Leuven, Bélgica))
Gambella, Massimiliano (IRCCS Ospedale Policlinico San Martino (Gènova, Itàlia))
Metafuni, Elisabetta (Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Roma, Itàlia))
Ciceri, Fabio (IRCCS Ospedale San Raffaele (Milà, Itàlia))
Saccardi, Riccardo (Careggi University Hospital (Florència, Itàlia))
Nicholson, Emma (The Royal Marsden Hospital (Londres, Regne Unit))
Tholouli, Elli (Manchester University NHS Foundation Trust)
Matthew, Collin (Northern Centre for Bone Marrow Transplantation (Newcastle Tyne, Regne Unit))
Potter, Victoria (King's College Hospital NHS Foundation Trust (Londres, Regne Unit))
Bloor, Adrian (University of Manchester (Regne Unit))
Besley, Caroline (University Hospitals Bristol and Weston NHSFT (Bristol, Regne Unit))
Roddie, Claire (University College London Hospital (Londres, Regne Unit))
Wilson, Keith (University Hospital of Cardiff (Regne Unit))
Nagler, Arnon (Tel Aviv University)
Campos, Antonio (Instituto Portugués de Oncologia do Porto. Francisco Gentil. E.P.E (Portugal))
Petersen, Soeren Lykke (Copenhagen University Hospital (Copenhagen, Dinamarca))
Folber, Frantisek (Masaryk University Hospital Brno (República Txeca))
Bader, Peter (Goethe University (Frankfurt, Alemanya))
Finke, Juergen (University of Freiburg (Alemanya))
Kroeger, Nicolaus (University Hospital Eppendorf (Alemanya))
Knelange, Nina (European Society for Blood and Marrow Transplantation (EBMT) Leiden Study Unit (Països Baixos))
de la Camara, Rafael (Hospital Universitario de la Princesa (Madrid))
Kersten, Maria José (Cancer Center Amsterdam and LYMMCARE (Països Baixos))
Mielke, Stephan (Cellular Therapy and immunobiology working party (CTIWP) of EBMT (Suècia))
Universitat Autònoma de Barcelona

Fecha:	2024
Resumen:	COVID-19 has been associated with high mortality in patients treated with Chimeric Antigen Receptor (CAR) T-cell therapy for hematologic malignancies. Here, we investigated whether the outcome has improved over time with the primary objective of assessing COVID-19-attributable mortality in the Omicron period of 2022 compared to previous years. Data for this multicenter study were collected using the MED-A and COVID-19 report forms developed by the EBMT. One-hundred-eighty patients were included in the analysis, 39 diagnosed in 2020, 35 in 2021 and 106 in 2022. The median age was 58. 9 years (min-max: 5. 2-78. 4). There was a successive decrease in COVID-19-related mortality over time (2020: 43. 6%, 2021: 22. 9%, 2022: 7. 5%) and in multivariate analysis year of infection was the strongest predictor of survival (p = 0. 0001). Comparing 2022 with 2020-2021, significantly fewer patients had lower respiratory symptoms (21. 7% vs 37. 8%, p = 0. 01), needed oxygen support (25. 5% vs 43. 2%, p = 0. 01), or were admitted to ICU (5. 7% vs 33. 8%, p = 0. 0001). Although COVID-19-related mortality has decreased over time, CAR T-cell recipients remain at higher risk for complications than the general population. Consequently, vigilant monitoring for COVID-19 in patients undergoing B-cell-targeting CAR T-cell treatment is continuously recommended ensuring optimal prevention of infection and advanced state-of-the art treatment when needed.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Adolescent ; Adult ; Aged ; Child ; Child, Preschool ; COVID-19 ; Europe ; Female ; Hematologic Neoplasms ; Humans ; Immunotherapy, Adoptive ; Male ; Middle Aged ; Receptors, Chimeric Antigen ; SARS-CoV-2 ; Survival Rate ; Treatment Outcome ; Young Adult
Publicado en:	Leukemia, Vol. 38 Núm. 9 (september 2024) , p. 1985-1991, ISSN 1476-5551

DOI: 10.1038/s41375-024-02336-1
PMID: 39043963

7 p, 1005.4 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Artículos > Artículos de investigación
Artículos > Artículos publicados